Resistell AG closes its series B first tranche of CHF 8.5m

Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF8.5M from new and existing investors. Investors include EIC Fund, TRUMPF Venture, OCCIDENT, Zürcher Kantonalbank, Launchpad, and private investors. The funds will be used to complete the company’s clinical trials for antibiotic susceptibility testing (AST) and for market entry of its R&D device Phenotech Research.